Cargando…

The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease

Synaptic degeneration and neuronal loss are early events in Alzheimer’s disease (AD), occurring long before symptom onset, thus making synaptic biomarkers relevant for enabling early diagnosis. The postsynaptic protein neurogranin (Ng) is a cerebrospinal fluid (CSF) biomarker for AD, also in the pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Kvartsberg, Hlin, Lashley, Tammaryn, Murray, Christina E., Brinkmalm, Gunnar, Cullen, Nicholas C., Höglund, Kina, Zetterberg, Henrik, Blennow, Kaj, Portelius, Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6338696/
https://www.ncbi.nlm.nih.gov/pubmed/30244311
http://dx.doi.org/10.1007/s00401-018-1910-3
_version_ 1783388473356451840
author Kvartsberg, Hlin
Lashley, Tammaryn
Murray, Christina E.
Brinkmalm, Gunnar
Cullen, Nicholas C.
Höglund, Kina
Zetterberg, Henrik
Blennow, Kaj
Portelius, Erik
author_facet Kvartsberg, Hlin
Lashley, Tammaryn
Murray, Christina E.
Brinkmalm, Gunnar
Cullen, Nicholas C.
Höglund, Kina
Zetterberg, Henrik
Blennow, Kaj
Portelius, Erik
author_sort Kvartsberg, Hlin
collection PubMed
description Synaptic degeneration and neuronal loss are early events in Alzheimer’s disease (AD), occurring long before symptom onset, thus making synaptic biomarkers relevant for enabling early diagnosis. The postsynaptic protein neurogranin (Ng) is a cerebrospinal fluid (CSF) biomarker for AD, also in the prodromal phase. Here we tested the hypothesis that during AD neurodegeneration, processing of full-length Ng into endogenous peptides in the brain is increased. We characterized Ng in post-mortem brain tissue and investigated the levels of endogenous Ng peptides in relation to full-length protein in brain tissue of patients with sporadic (sAD) and familial Alzheimer’s disease (fAD), healthy controls and individuals who were cognitively unaffected but amyloid-positive (CU-AP) in two different brain regions. Brain tissue from parietal cortex [sAD (n = 10) and age-matched controls (n = 10)] and temporal cortex [sAD (n = 9), fAD (n = 10), CU-AP (n = 13) and controls (n = 9)] were included and all the samples were analyzed by three different methods. Using high-resolution mass spectrometry, 39 endogenous Ng peptides were identified while full-length Ng was found to be modified including disulfide bridges or glutathione. In sAD parietal cortex, the ratio of peptide-to-total full-length Ng was significantly increased for eight endogenous Ng peptides compared to controls. In the temporal cortex, several of the peptide-to-total full-length Ng ratios were increased in both sAD and fAD cases compared to controls and CU-AP. This finding was confirmed by western blot, which mainly detects full-length Ng, and enzyme-linked immunosorbent assay, most likely detecting a mix of peptides and full-length Ng. In addition, Ng was significantly associated with the degree of amyloid and tau pathology. These results suggest that processing of Ng into peptides is increased in AD brain tissue, which may reflect the ongoing synaptic degeneration, and which is also mirrored as increased levels of Ng peptides in CSF. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00401-018-1910-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6338696
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-63386962019-02-01 The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease Kvartsberg, Hlin Lashley, Tammaryn Murray, Christina E. Brinkmalm, Gunnar Cullen, Nicholas C. Höglund, Kina Zetterberg, Henrik Blennow, Kaj Portelius, Erik Acta Neuropathol Original Paper Synaptic degeneration and neuronal loss are early events in Alzheimer’s disease (AD), occurring long before symptom onset, thus making synaptic biomarkers relevant for enabling early diagnosis. The postsynaptic protein neurogranin (Ng) is a cerebrospinal fluid (CSF) biomarker for AD, also in the prodromal phase. Here we tested the hypothesis that during AD neurodegeneration, processing of full-length Ng into endogenous peptides in the brain is increased. We characterized Ng in post-mortem brain tissue and investigated the levels of endogenous Ng peptides in relation to full-length protein in brain tissue of patients with sporadic (sAD) and familial Alzheimer’s disease (fAD), healthy controls and individuals who were cognitively unaffected but amyloid-positive (CU-AP) in two different brain regions. Brain tissue from parietal cortex [sAD (n = 10) and age-matched controls (n = 10)] and temporal cortex [sAD (n = 9), fAD (n = 10), CU-AP (n = 13) and controls (n = 9)] were included and all the samples were analyzed by three different methods. Using high-resolution mass spectrometry, 39 endogenous Ng peptides were identified while full-length Ng was found to be modified including disulfide bridges or glutathione. In sAD parietal cortex, the ratio of peptide-to-total full-length Ng was significantly increased for eight endogenous Ng peptides compared to controls. In the temporal cortex, several of the peptide-to-total full-length Ng ratios were increased in both sAD and fAD cases compared to controls and CU-AP. This finding was confirmed by western blot, which mainly detects full-length Ng, and enzyme-linked immunosorbent assay, most likely detecting a mix of peptides and full-length Ng. In addition, Ng was significantly associated with the degree of amyloid and tau pathology. These results suggest that processing of Ng into peptides is increased in AD brain tissue, which may reflect the ongoing synaptic degeneration, and which is also mirrored as increased levels of Ng peptides in CSF. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00401-018-1910-3) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2018-09-22 2019 /pmc/articles/PMC6338696/ /pubmed/30244311 http://dx.doi.org/10.1007/s00401-018-1910-3 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Paper
Kvartsberg, Hlin
Lashley, Tammaryn
Murray, Christina E.
Brinkmalm, Gunnar
Cullen, Nicholas C.
Höglund, Kina
Zetterberg, Henrik
Blennow, Kaj
Portelius, Erik
The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease
title The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease
title_full The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease
title_fullStr The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease
title_full_unstemmed The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease
title_short The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease
title_sort intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic alzheimer’s disease
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6338696/
https://www.ncbi.nlm.nih.gov/pubmed/30244311
http://dx.doi.org/10.1007/s00401-018-1910-3
work_keys_str_mv AT kvartsberghlin theintactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease
AT lashleytammaryn theintactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease
AT murraychristinae theintactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease
AT brinkmalmgunnar theintactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease
AT cullennicholasc theintactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease
AT hoglundkina theintactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease
AT zetterberghenrik theintactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease
AT blennowkaj theintactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease
AT porteliuserik theintactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease
AT kvartsberghlin intactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease
AT lashleytammaryn intactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease
AT murraychristinae intactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease
AT brinkmalmgunnar intactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease
AT cullennicholasc intactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease
AT hoglundkina intactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease
AT zetterberghenrik intactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease
AT blennowkaj intactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease
AT porteliuserik intactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease